Terapia Intensiva

Risco de complicações pós-operatórias após cirurgias eletivas em pacientes com COVID-19 ativa ou resolvida nos EUA – Cirurgia realizada de 0 a 4 semanas após Covid-19 está associada a risco bastante aumentado de complicações pós-cirúrgicas; cirurgia feita de 4 a 8 semanas depois da infecção ainda está associada com risco aumentado de pneumonia.

7 Dez, 2021 | 11:50h

The Risk of Postoperative Complications following Major Elective Surgery in Active or Resolved COVID-19 in the United States – Annals of Surgery

Conteúdos relacionados:

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

---

Série de casos com 139 adolescentes e adultos jovens com suspeita de miocardite após vacina de mRNA mostrou que a maioria deles teve curso clínico leve e resolução rápida dos sintomas.

7 Dez, 2021 | 11:46h

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

Comunicado de imprensa: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

---

Cuidado de idosos e pessoas que necessitam de cuidados paliativos com COVID-19: orientação da Australian National COVID-19 Clinical Evidence Taskforce.

7 Dez, 2021 | 11:41h

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

---

Diretriz IDSA sobre o tratamento de infecções por enterobactérias produtoras de AmpC betalactamase, Acinetobacter baumannii resistente a carbapenêmicos e Stenotrophomonas maltophilia.

7 Dez, 2021 | 11:36h

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – Clinical Infectious Diseases

---

Diretriz S2k | Diagnóstico e tratamento do envenenamento por monóxido de carbono.

7 Dez, 2021 | 11:35h

S2k guideline diagnosis and treatment of carbon monoxide poisoning – German Medical Science

---

Revisão clínica | Tratamento da pneumonia em pacientes criticamente doentes.

7 Dez, 2021 | 11:33h

Management of pneumonia in critically ill patients – The BMJ

---

Ensaios clínicos randomizados na terapia intensiva: passado, presente e futuro.

3 Dez, 2021 | 11:00h

Randomised clinical trials in critical care: past, present and future – Intensive Care Medicine

 

Comentário no Twitter

RCTs in critical care, history, major challenges & limitations, recent developments trying to solve some of these
📊conventional & novel RCTs
📊rationale for choosing methodological approach (advantages/potential disadvantages – pros/cons)@CritCareReviewshttps://t.co/kjCw7dFuou pic.twitter.com/xS9lHK4cuY

— Intens Care Med (@yourICM) December 2, 2021

 

---

Estudo de coorte retrospectivo | A maioria dos medicamentos imunossupressores, com exceção do rituximabe, não foi associada com risco aumentado de uso de ventilação mecânica ou morte em pacientes internados com Covid-19.

2 Dez, 2021 | 11:32h

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Comentários:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

 

Comentário no Twitter

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj

— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021

 

---

Revisão de evidência atual | Fluvoxamina para tratamento precoce da infecção por SARS-CoV-2.

2 Dez, 2021 | 11:30h

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence – Drugs

Conteúdos relacionados:

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

---

Mortalidade total de pacientes de COVID na Alemanha que receberam ECMO durante as primeiras 3 ondas da pandemia.

1 Dez, 2021 | 15:37h

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic – Critical Care

---